Anlon Healthcare Limited reported a 42.98% year-on-year increase in consolidated total income to ₹172.22 crore for FY26, driven by expanding demand across its pharmaceutical intermediate and API portfolio. Profit after tax grew 41.77% to ₹29.09 crore, while EBITDA increased 47.55% to ₹47.77 crore. The company attributed this performance to improving operational efficiencies and disciplined execution across key business verticals. Management stated it remains confident of delivering approximately 30% revenue CAGR over the next three years while maintaining EBITDA margins in the range of 25 to 30%.

For the fourth quarter ended March 31, 2026, total income stood at ₹50.90 crore compared to ₹48.97 crore in Q4 FY25. Profit before tax for the quarter was broadly stable at ₹14.44 crore versus ₹15.49 crore, while reported PAT of ₹11.07 crore was lower than the ₹16.65 crore in the corresponding quarter. The decline was primarily due to higher operating and development expenses as the company scales its platform.

Financial Performance

Strategic Developments

The company completed the acquisition of Apiqo Organics Private Limited and Bizotic Life Science during the year, strengthening backward integration and adding substantial capacity. With these initiatives, the combined installed capacity has expanded to approximately 1400 to 1600 metric ton per annum. Anlon Healthcare is also developing three molecules for two global innovators to reinforce its long-term strategy to build a scalable custom manufacturing platform.

Future Guidance

Management guided for revenue between ₹380 to 400 crore for FY27, with visibility of an order book around ₹280 to 300 crore. The company expects to be cash flow positive on an annual basis by the end of FY27. A new capex of approximately ₹130 crore is planned for expansion at the existing premises, with construction expected to start by the end of June 2026 and commercial production targeted by Q1 FY28. Funding for the capex will be sourced through a term loan of ₹65 to 70 crore and internal accruals.

Anlon Healthcare Limited has reported its audited standalone and consolidated financial results for the financial year ended March 31, 2026, alongside an investor presentation for Q4 and FY26. The company recorded a 42.98% increase in consolidated total income to ₹172.22 crore, driven by strong operational performance and strategic acquisitions including Bizotic Lifescience and Apiqo Organics. The Board of Directors approved the results at a meeting held on May 29, 2026.

Financial Performance

For the financial year FY26, Anlon Healthcare achieved a consolidated total income of ₹172.22 crore, a rise from ₹120.46 crore in FY25. Revenue from operations for the year stood at ₹171.97 crore, compared to ₹120.29 crore in the prior year. The company's consolidated net profit for the period improved to ₹29.09 crore from ₹20.52 crore in the previous year. Consolidated EBITDA increased by 47.55% to ₹47.77 crore, with an EBITDA margin of 27.74%.

On a standalone basis for FY26, total income was recorded at ₹176.26 crore, while net profit for the year was ₹27.81 crore. Earnings per share (EPS) on a basic and diluted basis for the year were reported at ₹5.93. The statutory auditors, R V D & Co., provided an unmodified opinion on the standalone and consolidated annual financial results.

Q4FY26 Results

For the quarter ended March 31, 2026 (Q4FY26), the company reported a total income of ₹50.90 crore, compared to ₹48.97 crore in Q4FY25. Net profit for Q4FY26 stood at ₹11.07 crore, down from ₹16.65 crore in the corresponding quarter of the previous year. The EBITDA for the quarter was ₹15.31 crore, with a margin of 30.07%.

The following table summarises the key standalone financial metrics for FY26:

Key Developments

During the year, the company completed the acquisition of Bizotic Lifescience, which is now a subsidiary of Anlon Healthcare, strengthening its manufacturing platform. Apiqo Organics continues to strengthen backward integration capabilities. The company also continued development of 3 molecules for 2 global innovator companies under the CDMO business vertical and diversified into the Industrial & Fine Chemicals segment. The investor presentation highlights a combined installed capacity expected to reach 1,400–1,600 MTPA post expansion and plans for 3–5 DMF filings in FY 2026-27.

Board and Compliance

The filing was submitted in compliance with Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. A newspaper advertisement confirming the publication of these results was released on May 30, 2026. The investor presentation for Q4 & FY26 was uploaded on the company's website on June 03, 2026.